메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Bowtie Secures Series C Fundraising From Sun Life

[ 메디채널 김갑성 기자 ] New Funding Fuels Growth in Medical Insurance and Innovation in Preventive Healthcare HONG KONG, July 18, 2025 -- Bowtie, Hong Kong's first virtual insurer[1], is proud to announce securing up to US$70 million in its Series C funding round. Led by Sun Life Hong Kong Limited ("Sun Life"), this marks the largest funding round for digital health insurers in Asia with a direct-to-consumer model. Bowtie continues to lead in Hong Kong's digital insurance market, ranking first in the direct channel[2], and securing the 9th position across all dist
- 김갑성 기자
- 2025-07-18 11:25
MFDS Clears DeepQure's HyperQure™ for Clinical Trial in Atrial Fibrillation

SEOUL, South Korea, July 18, 2025 -- DeepQure announced today that South Korea's Ministry of Food and Drug Safety (MFDS) has approved a clinical trial of HyperQure™ RDM System, the company's novel laparoscopic renal denervation (RDN) system, for the treatment of atrial fibrillation (AF). The trial is designed to evaluate the safety and efficacy of laparoscopic RDN in patients with recurrent AF following pulmonary vein isolation (PVI) and resistant hypertension. It will be conducted as a multicenter, prospective, single-arm, open-label exploratory study. HyperQure™ is a next-gene
- 김갑성 기자
- 2025-07-18 10:59
Fujitsu and Acer Medical trial AI service that assesses future disease risk in elderly patients through gait pattern abnormality detection

[ 메디채널 김갑성 기자 ] KAWASAKI, Japan and NEW TAIPEI CITY, July 18, 2025 -- Fujitsu Limited and Acer Medical Inc., a provider of AI-powered medical imaging and preventative medicine, today announced a collaborative agreement to develop "aiGait" powered by Uvance, a solution that leverages Fujitsu's advanced skeleton recognition AI technology to detect gait pattern abnormalities, and provide gait quantization to healthcare professionals to support the early diagnosis of dementia and Parkinson's disease. The technology is part of "Fujitsu Kozuchi for Vision" from the Fujitsu Uva
- 김갑성 기자
- 2025-07-18 09:34
Lifezoom Launches Veyra Series: Flexible Red Light Therapy Panels That Redefine Home Wellness

NEW YORK, July 17, 2025 -- Lifezoom, a pioneer of red light therapy in the USA, is excited to expand with the new industry-leading Veyra Series, red light therapy panels that mix creativity, adaptability, and health-focused design. Now, with two launch products, Veyra C and Veyra S, this versatile red light technology, built on a flexible silicone base material, is available throughout the U.S and Europe at the starting price of $249. After years of research and development, the Lifezoom engineering team from Iowa's hardworking community has brought to market a product that not
- 김갑성 기자
- 2025-07-17 21:03
Co-PSMA trial: Recruitment successfully completed

SYDNEY, July 17, 2025 -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT) led by Prof Louise Emmett at St Vincent's Hospital Sydney has now completed study enrolment, with all participants having been imaged. The study is evaluating the performance of Clarity's diagnostic product, 64Cu-SAR-b
- 김갑성 기자
- 2025-07-17 21:01
RapidClaims Receives Frost & Sullivan's 2025 North American Healthcare IT-Software and Services Technology Innovation Leadership Recognition for Excellence in AI-Driven RCM Automation

[ 메디채널 김갑성 기자 ] Recognized for driving operational efficiency and accelerating customer acquisition through AI-powered automation and a highly adaptive deployment model SAN ANTONIO, July 17, 2025 -- Frost & Sullivan is pleased to announce that RapidClaims has been recognized with the 2025 North American Healthcare IT-Software and Services Technology Innovation Leadership Recognition in the healthcare IT industry for its outstanding achievements in product innovation, operational excellence, and customer-centric design in the revenue cycle management (RCM) space. This recognition
- 김갑성 기자
- 2025-07-17 21:00
SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate

Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant Interim results from the Phase 1/2 trial expected by 2027, aimed at entering the high-immunogenicity vaccine market "Our SKYCellflu platform with our adjuvanted vaccine experience will lay a strong foundation for future success." SEONGNAM, South Korea, July 17, 2025 -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company has submitted an In
- 김갑성 기자
- 2025-07-17 19:00
Yili Representative Attends the 8th Australia-China CEO Roundtable Meeting

BEIJING, July 17, 2025 -- On July 15, the 8th Australia-China CEO Roundtable Meeting was held in Beijing. Liu Chunxi, Senior Executive President of Yili Group, participated and delivered a speech. Liu stated that Australia boasts high-quality agricultural and pastoral resources, along with extensive expertise in dairy cattle breeding, pasture management, and dairy product R&D and manufacturing. Meanwhile, China offers a stable and positive macroeconomic environment, a thriving health food consumption market, and leadership in digitalization and low-carbon technology applications. The two
- 황정호 기자
- 2025-07-17 17:39
Manulife Survey Reveals Hongkongers' New Perspective on Longevity--Prioritizing Living Well on Their Own Terms Over Simply Living Longer

77%[1] of respondents define health as "living independently and doing what's important", prioritizing a meaningful life over simply living longer. Many would prefer a fulfilling life to age 75 over living to 80 in an ordinary manner—reflecting a shift in how longevity is traditionally perceived. Resilience across physical, financial, and mental well-being—alongside strong family support—is key to aging well. With health issues to emerge as early as age 39 on average among respondents, the three most anticipated areas of increased spending are medication (43%), major illnesses and
- 황정호 기자
- 2025-07-17 17:23
Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery

MILAN, July 17, 2025 -- A recently published five-year pharmacovigilance study confirms the excellent safety profile of a fixed-dose combination eye drop containing an anti-inflammatory steroid and a quinolone antibiotic, developed by NTC, indicated for the prevention and treatment of inflammation and prevention of infection following cataract surgery in adults. The study was submitted when nearly 4 million patients across about 60 countries worldwide were treated with this drug. Conducted by Italian researchers and supported by NTC, the study analyzed public safety data registered in
- 김갑성 기자
- 2025-07-17 17:00

이전

41 42 43 44 45 46 47 48 49 50

많이 본 기사

최근기사

2025-09-08_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 08일 19시 00분